sr141716 has been researched along with mocetinostat in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, K; Egashira, N; Fujioka, M; Fujiwara, M; Hasebe, N; Hayakawa, K; Hazekawa, M; Irie, K; Iwasaki, K; Mishima, K; Nozako, M; Orito, K | 1 |
| Feleder, C; Gertzberg, N; James, J; Johnson, A; MacDonald, H; Neumann, PH; Peng, J; Russo, V | 1 |
2 other study(ies) available for sr141716 and mocetinostat
| Article | Year |
|---|---|
Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism.
Topics: Animals; Behavior, Animal; Cannabidiol; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Dronabinol; Functional Laterality; Glutamic Acid; Infarction, Middle Cerebral Artery; Male; Mice; Motor Activity; Neuroprotective Agents; Perfusion; Peroxidase; Piperidines; Pyrazoles; Receptors, Cannabinoid; Rimonabant; Tetrazolium Salts; Time Factors | 2007 |
The intracerebroventricular injection of rimonabant inhibits systemic lipopolysaccharide-induced lung inflammation.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Administration Schedule; Injections, Intraventricular; Lipopolysaccharides; Lung; Male; Peroxidase; Piperidines; Pneumonia; Pulmonary Edema; Pyrazoles; Rats; Rats, Sprague-Dawley; Rimonabant; Signal Transduction; Time Factors; Toll-Like Receptor 4 | 2015 |